Structure via PubChem · Public domain (PubChem)
voglibose
Sign in to saveAlso known as A-71100, AO-128, Basen, Glustat
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.
In the Vinony graph
Vinony's link graph records 142 inbound references to voglibose, and connects out to metformin, alogliptin and anti-diabetic medication.
It is catalogued under topics including Alpha-glucosidase inhibitors, Amino sugars and Drugs with no legal status.
Vinony links it to 8 Wikipedia language editions.
Chemical data
- Formula
- C10H21NO7
- Molecular weight
- 267.28 g/mol
- IUPAC name
- (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
- SMILES
- C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
- InChIKey
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N
- XLogP
- -4.1
- Polar surface area
- 154 Ų
- H-bond donors
- 8
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1994
- Admin. routes
- oral
- Indications
- diabetes mellitus, type 2 diabetes mellitus
via ChEMBL · EBI
Research
426 papers- Synthesis of (+)-Voglibose.Organic letters · 2025
- [Voglibose].Nihon rinsho. Japanese journal of clinical medicine · 1997
- The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials.Pharmacological research · 2020
- Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.Current medicinal chemistry · 2006
- Efficacy of voglibose in type 2 diabetes.Expert opinion on pharmacotherapy · 2014
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 267.131802
- Has use
- medication
Show 6 more facts
- Commons category
- Voglibose
- defined daily dose
- 0.6
- chemical formula
- C₁₀H₂₁NO₇
- canonical SMILES
- C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO
- isomeric SMILES
- C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
- medical condition treated
- diabetes
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Efficacy
- References
- Further reading
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
Excerpted from Wikipedia’s “voglibose” article, available under the CC BY-SA 4.0 licence.
Available in 8 languages
via Wikidata sitelinks · CC0